MediWound Ltd. Raises $30 Million in Direct Offering
Ticker: MDWD · Form: 6-K · Filed: Sep 29, 2025 · CIK: 1593984
| Field | Detail |
|---|---|
| Company | Mediwound Ltd. (MDWD) |
| Form Type | 6-K |
| Filed Date | Sep 29, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Key Dollar Amounts | $30 Million |
| Sentiment | neutral |
Sentiment: neutral
Topics: offering, capital-raise, shares
TL;DR
MediWound just raised $30M via a direct share offering. Bullish.
AI Summary
On September 29, 2025, MediWound Ltd. announced a registered direct offering to raise $30 million through the sale of ordinary shares. The company is based in Yavne, Israel, and operates in the medicinal chemicals and botanical products sector.
Why It Matters
This capital raise provides MediWound Ltd. with additional funds, potentially for research, development, or expansion of its product lines in the pharmaceutical sector.
Risk Assessment
Risk Level: medium — Direct offerings can dilute existing shareholders and may indicate a need for immediate capital, suggesting potential financial pressures or aggressive growth plans.
Key Numbers
- $30.0M — Registered Direct Offering (Funds raised by MediWound Ltd.)
Key Players & Entities
- MediWound Ltd. (company) — Registrant
- $30 million (dollar_amount) — Amount of registered direct offering
- September 29, 2025 (date) — Date of press release and offering announcement
- Yavne, Israel (location) — Company headquarters
FAQ
What is the purpose of the $30 million registered direct offering?
The filing does not specify the exact use of the funds, but such offerings typically provide capital for operations, research and development, or strategic initiatives.
When was the press release announcing the offering issued?
The press release was issued on September 29, 2025.
What type of securities were offered in the direct offering?
Ordinary shares of MediWound Ltd. were offered.
Where is MediWound Ltd. headquartered?
MediWound Ltd. is headquartered at 42 Hayarkon Street, Yavne, 8122745, Israel.
Does MediWound Ltd. file annual reports on Form 20-F?
Yes, the company indicates it files annual reports under cover of Form 20-F.
Filing Stats: 315 words · 1 min read · ~1 pages · Grade level 10.4 · Accepted 2025-09-29 08:49:18
Key Financial Figures
- $30 Million — s release entitled "MediWound Announces $30 Million Registered Direct Offering of Ordinary
Filing Documents
- zk2533816.htm (6-K) — 11KB
- exhibit_99-1.htm (EX-99.1) — 14KB
- image00001.jpg (GRAPHIC) — 4KB
- 0001178913-25-003411.txt ( ) — 31KB
From the Filing
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________ FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2025 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant's name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F EXPLANATORY NOTE On September 29, 2025, MediWound Ltd. (the "Company") issued a press release entitled "MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares". A copy of this press release is attached to this Report of Foreign Private Issuer on Form 6-K (this "Form 6-K") as Exhibit 99.1. The content of this report on Form 6-K (including the information contained in Exhibit 99.1), is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the SEC on April 28, 2014, March 24, 2016, March 19, 2018, March 25, 2019, February 25, 2020, May 15, 2021 August 9, 2022, August 15, 2023, and March 19, 2025 (Registration Nos. No. 333-195517, 333-210375, 333-223767, 333-230487, 333-236635, 333-255784, 333-266697, 333-273997 and 333-285897, respectively) and on Form F-3 filed with the SEC on March 31, 2023, August 29, 2024 and March 19, 2025 (Registration Nos. 333-268297, 333-281843 and 333-285908, respectively. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: September 29, 2025 MEDIWOUND LTD. By: /s/ Hani Luxenburg Name: Hani Luxenburg Title: Chief Financial Officer 3 EXHIBIT INDEX The following exhibit is filed as part of this Form 6-K: Exhibit Description 99.1 Press release dated September 29, 2025 entitled "MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares". 4